The 19th International Photodynamic Association (IPA) Congress will convene in Shanghai from June 10-16, 2025. Asieris Pharmaceuticals (Stock Code: 688176.SH) will participate under the theme “Illuminating Tomorrow, Healing with Light” showcasing two globally innovative photodynamic therapy (PDT).
Among them, APL-1702—the world’s first and only non-invasive drug-device combination for cervical precancerous lesions—has demonstrated confirmed efficacy through an international multicenter Phase III clinical study. It is poised to provide a fertility-friendly, non-invasive solution for cervical cancer prevention systems in China and globally.
Concurrently, Asieris will exhibit APL-1706, its drug for bladder cancer diagnosis or surgical procedures. APL-1706 is currently the only approved optical imaging agent for assisting bladder cancer diagnosis or surgical procedures worldwide. The combined use of APL-1706 and blue light cystoscopy (BLC) for managing non-muscle invasive bladder cancer (NMIBC) is included in international and domestic guidelines/expert consensus.
The IPA is the preeminent global academic organization in photodynamic therapy, hosting its prestigious biennial congress—often hailed as the “Olympics of PDT.” Centered on the theme “Integrating Photodynamic Basic Research and Clinical Applications for Human Health,” IPA 2025 will gather leading scholars, clinical experts, and industry leaders to explore cutting-edge advancements and the vast potential of PDT.
A pioneer in photodynamic therapy for gynecological precancerous lesions, Prof. Peter Hillemanns will deliver an invited lecture on “Efficacy of APL-1702 in Patients with Cervical High-Grade Squamous Intraepithelial Lesions (HSIL): A Subgroup Analysis of the APRICITY1 Study.” He serves as Director of the Department of Gynecology and Obstetrics at Hannover Medical School, Director of the Claudia von Schilling Cancer Center (CCC Hannover), and Spokesperson for the Comprehensive Cancer Center Lower Saxony, applying his specialization in gynecology and oncology.
Additionally, in the Gynecology Session (Part 1), the session chair Prof. Fei Chen from Peking Union Medical College Hospital, Chinese Academy of Medical Sciences will present APL-1702 study data.
Additionally, Prof. Lihua Qiu (Renji Hospital, Shanghai Jiao Tong University School of Medicine) and other prominent experts will lead keynote speeches on the latest clinical applications of PDT for cervical intraepithelial lesions.
[HIGHLIGHTED ACADEMIC AGENDA]
- June 12, 08:45–09:05
Session: Featured Presentation
Speaker: Prof. Peter Hillemanns
Topic: Efficacy of APL-1702 in patients with cervical HSIL: A subgroup analysis of the APRICITY study
- June 12, 10:15–12:15
Session: Oral Presentation
Session Chair: Prof. Peter Hillemanns & Prof. Fei Chen
Topic: Gynecology Session 1
- June 14, 13:45–15:45
Session: Oral Presentation
Session Chair: Prof. Lihua Qiu
Topic: Gynecology Session 2
IPA 2025 is not only a premier academic event but also a vital platform for advancing the industrialization of photodynamic therapy. Asieris anticipates that deep dialogues with global experts will accelerate APL-1702’s international expansion, contributing Chinese expertise and solutions to the global strategy of “Accelerating the Elimination of Cervical Cancer.”
Join us to witness the highlights of this landmark event!
Venue: Shanghai International Convention Center (2727 Binjiang Avenue, Pudong, Shanghai)
Asieris Booth: A02,3rd Floor
- APRICITY is a prospective, randomized, double-blind, placebo-controlled international multicenter Phase III clinical study designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL. The study met its primary endpoint, together with a robust safety profile.
- Note: As of this release date, APL-1702 has yet to be approved in China and is presented solely for display at the 2025 IPA. The information provided is not intended for patients. For more details about the condition, please consult a healthcare professional.